GLP-1 pegylated compounds
    4.
    发明授权
    GLP-1 pegylated compounds 失效
    GLP-1聚乙二醇化化合物

    公开(公告)号:US08183340B2

    公开(公告)日:2012-05-22

    申请号:US11913365

    申请日:2006-05-11

    IPC分类号: A61K38/26 C07K14/605 A61P3/10

    CPC分类号: C07K14/605 A61K47/60

    摘要: The invention provides GLP-1 compounds coupled to two polyethylene glycol molecule or derivative thereof, resulting in a biologically active peptide with an extended half-life and a slower clearance when compared to that of unPEGylated peptide. These PEGylated GLP-1 compounds and compositions are useful in treating conditions or disorders benefited by lowering blood glucose, decreasing food intake, decreasing gastric or intestinal emptying, increasing beta (β) cell population, or decreasing gastric or intestinal motility.

    摘要翻译: 本发明提供了与两个聚乙二醇分子或其衍生物偶联的GLP-1化合物,当与未PEG化肽相比时,产生具有延长的半衰期和较慢清除率的生物活性肽。 这些聚乙二醇化GLP-1化合物和组合物可用于治疗通过降低血糖,减少食物摄取,减少胃或肠排空,增加β(β)细胞群体或减少胃或肠运动而受益的病症或病症。

    Glp-1 Pegylated Compounds
    10.
    发明申请
    Glp-1 Pegylated Compounds 失效
    Glp-1聚乙二醇化化合物

    公开(公告)号:US20090215981A1

    公开(公告)日:2009-08-27

    申请号:US11913365

    申请日:2006-05-11

    CPC分类号: C07K14/605 A61K47/60

    摘要: The invention provides GLP-1 compounds coupled to two polyethylene glycol molecule or derivative thereof, resulting in a biologically active peptide with an extended half-life and a slower clearance when compared to that of unPEGylated peptide. These PEGylated GLP-1 compounds and compositions are useful in treating conditions or disorders benefited by lowering blood glucose, decreasing food intake, decreasing gastric or intestinal emptying, increasing beta (β) cell population, or decreasing gastric or intestinal motility.

    摘要翻译: 本发明提供了与两个聚乙二醇分子或其衍生物偶联的GLP-1化合物,当与未PEG化肽相比时,产生具有延长的半衰期和较慢清除率的生物活性肽。 这些聚乙二醇化GLP-1化合物和组合物可用于治疗通过降低血糖,减少食物摄入,减少胃或肠排空,增加β(β)细胞群体或减少胃或肠蠕动而受益的病症或障碍。